



Cellergy Pharma

Targeting Allergic Disease at Its Source

Ronald P. Dudek
President and Founder

rdudek@cellergypharma.com

425-647-7446

<https://cellergypharma.com>

The Problem – Severe Allergic Asthma




- Your child is at a soccer game, and has forgotten her inhaler.
- High pollen levels have triggered a severe allergic asthma attack.
- Your child is having difficulty breathing and her lips are turning blue.
- The coach rushes her to the emergency room.

The Problem – Food Allergy



- Your child is at a birthday party, and takes a bite of a cookie offered by another child.
- His lips and tongue begin to swell up.
- He begins to wheeze and is experiencing shortness of breath.
- The host of the birthday party frantically calls you, asking what to do.


Imagine a Better Life




Cellergy Pharma

- Imagine a product that is administered one-time, and that eliminates all allergic asthma symptoms.
- Imagine a product that is administered one-time, and that allows your child to eat any food without suffering the symptoms of food allergy.
- Imagine Cellergy Pharma.

Asthma emergency department (ED) visits rate* (per 10,000 population) by age group and year



Number of Asthma Deaths by Year



Severe Allergic Asthma

- There is no cure for severe allergic asthma.
- Corticosteroids can reduce exacerbations, but are not cures, and have significant long-term side effects.
- Antibody drugs, which require once or twice monthly injections for life, can reduce exacerbations, but are not cures.
- Notwithstanding, severe exacerbations and deaths continue to occur.

'She was suffocating': NC family hopes tragedy leads to food allergy awareness

A small bite of a cookie changed a North Carolina family forever. They hope their tragic story will raise awareness for those living with severe allergies.




Severe Food Allergy

- There are no approved drugs for treating severe food allergy.
- The afflicted live under constant fear of eating the wrong food, greatly diminishing their quality of life.
- Anaphylaxis and death can result.

The Solution




- A first-in-class immunotherapy that eliminates the cause of atopic allergic disease.
- A product that is truly disease-modifying, and not merely symptom-reducing.
- A product that produces enduring efficacy from a single product dose.
- A product that allows individuals with severe allergic disease, and their loved ones, to pursue a healthy, worry-free life.



Our Product


- Chimeric antigen receptor-engineered T cells (CAR T cells).
- Produced from the patient's own cells.
- Specifically target and eliminate the cells that cause allergic disease.
- Persisting CAR T cells provide enduring efficacy.

Mechanism of Action



- CAR T cells target and eliminate the cells that produce immunoglobulin E (IgE), the cause of all atopic allergic diseases.






The Uncontrolled Severe Allergic Asthma Market: US

- Our beachhead market is adults with uncontrolled severe allergic asthma.
- \approx 4,000 yearly fatalities occur within this group.
- We will expand into treating children with uncontrolled severe allergic asthma.





The Severe Food Allergy Market: US

- Our second market is adults with severe food allergy who have experienced a severe allergic reaction including anaphylaxis.
- We will initially target adults who have experienced one or more emergency department visits within the past year.
- We will expand into treating children with severe food allergy.

The Team



Ronald P. Dudek
President and Founder

- An experienced cell therapy industry executive and successful four-time CAR T cell startup serial entrepreneur.
- Founded Living Pharma, the first-in-the world Adapter CAR company, which was acquired 1.5 years after founding.
- Extensive cell therapy industry experience includes executive roles at Miltenyi Biomedicine, Juno Therapeutics, Xcyte Therapies, Aastrom Biosciences, and Miltenyi Biotec.
- <https://www.linkedin.com/in/cartcells/>



Zhengyu "Mark" Ma, MS, MBBS, PhD
Chief Science Officer and Founder

- The inventor of Cellergy's CAR's.
- The head of an immunology research lab at the Nemours Children's Hospital.
- Extensive research experience includes working at the world's leading CAR T cell academic institution, the University of Pennsylvania.
- <https://www.linkedin.com/in/zhengyu-ma-3737ab6/>
- <https://www.bio.udel.edu/people/zma>



Thank You!

Contact Us:

E-mail: rdudek@cellergypharma.com

Phone: 1-425-647-7446

LinkedIn: <https://www.linkedin.com/in/cartcells/>

Website: <https://cellergypharma.com>

